Abstract
Recent studies have shed light on a number of important obstacles to safe and effective gene transfer to the respiratory tract with recombinant AAV vectors. Among these are blocks at the level of receptor binding and internalizations, evasion of proteasomal degradation, inefficiency of nuclear entry, and nuclear factors that inhibit the conversion of rAAV genomes into active double-stranded DNA form. Other important issues have been the size constraints of the vector, the lack of retention of episomal forms of the vector genome, and immune responses which may limit the efficiency of repeated doses of rAAV. Each of these potential obstacles has been addressed with new vector designs. In addition, the availability of an abundance of novel rAAV serotypes, each with its own receptor tropism, has expanded the range of possibilities for long-term success of gene therapy in the respiratory tract.
Keywords: cystic fibrosis (cf), alpha antitrypsin(aat), raav-mediated gene therapy, capsid mutants, proteasomal degradation, xenografts, tyrosine kinase inihbitors, split-intron vector
Current Gene Therapy
Title: Recent Developments in Recombinant AAV-Mediated Gene Therapy for Lung Diseases
Volume: 5 Issue: 3
Author(s): Terence R. Flotte
Affiliation:
Keywords: cystic fibrosis (cf), alpha antitrypsin(aat), raav-mediated gene therapy, capsid mutants, proteasomal degradation, xenografts, tyrosine kinase inihbitors, split-intron vector
Abstract: Recent studies have shed light on a number of important obstacles to safe and effective gene transfer to the respiratory tract with recombinant AAV vectors. Among these are blocks at the level of receptor binding and internalizations, evasion of proteasomal degradation, inefficiency of nuclear entry, and nuclear factors that inhibit the conversion of rAAV genomes into active double-stranded DNA form. Other important issues have been the size constraints of the vector, the lack of retention of episomal forms of the vector genome, and immune responses which may limit the efficiency of repeated doses of rAAV. Each of these potential obstacles has been addressed with new vector designs. In addition, the availability of an abundance of novel rAAV serotypes, each with its own receptor tropism, has expanded the range of possibilities for long-term success of gene therapy in the respiratory tract.
Export Options
About this article
Cite this article as:
Flotte R. Terence, Recent Developments in Recombinant AAV-Mediated Gene Therapy for Lung Diseases, Current Gene Therapy 2005; 5 (3) . https://dx.doi.org/10.2174/1566523054064986
DOI https://dx.doi.org/10.2174/1566523054064986 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Synthesis, Antifungal Evaluation and Molecular Docking Studies on 2- thioxoimidazolidin-4-one Derivatives
Medicinal Chemistry Pharmacists' Knowledge and Attitudes Towards Upper Respiratory Infections (URI) in Iran: A Cross Sectional Study
Reviews on Recent Clinical Trials Serratia, No Longer an Uncommon Opportunistic Pathogen – Case Series & Review of Literature
Infectious Disorders - Drug Targets An Update on the Systemic Therapy of Malignant Salivary Gland Cancers: Role of Chemotherapy and Molecular Targeted Agents
Current Medicinal Chemistry - Anti-Cancer Agents Magnetic Resonance Imaging Findings of Sixth Cranial Nerve Palsies in Patients Presenting with Diplopia
Current Medical Imaging Is Technical-Grade Chlordane an Obesogen?
Current Medicinal Chemistry A Review of Titanium Di Oxide Nanoparticles - Synthesis, Applications and Toxicity Concerns
Nanoscience & Nanotechnology-Asia Evaluation of Topical Black Seed Oil in the Treatment of Allergic Rhinitis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Targets for the Treatment of Erectile Dysfunction: Is NO/cGMP Still the Answer?
Recent Patents on Cardiovascular Drug Discovery Preface
Current Drug Targets - Inflammation & Allergy Pivotal Pathogenic and Biomarker Role of Chlamydia Pneumoniae in Neurovascular Diseases
Current Neurovascular Research Morphometric Analysis of the Fronto-maxillary Sinuses in Adult Patients with Traumatic Septal Deviations
Current Medical Imaging Patent Selections:
Recent Patents on Anti-Infective Drug Discovery Absorption, Pharmacokinetics and Disposition Properties of Solid Lipid Nanoparticles (SLNs)
Current Drug Metabolism Use of Non-steroidal Anti-inflammatory Drugs in Pregnancy: Impact on the Fetus and Newborn
Current Drug Metabolism Comparison of High-Sensitive CRP, RDW, PLR and NLR between Patients with Chronic Obstructive Pulmonary Disease and Chronic Heart Failure
Current Respiratory Medicine Reviews Venous Collateral Circulation of the Extracranial Cerebrospinal Outflow Routes
Current Neurovascular Research Functional Chemokine Receptors in Allergic Diseases: Is CCR8 a Novel Therapeutic Target?
Mini-Reviews in Medicinal Chemistry Should We Develop an Inhaled Anti-pneumococcal Vaccine for Adults?
Current Medicinal Chemistry - Anti-Infective Agents Adolescent Asthma Management
Current Pediatric Reviews